JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

INSULIN PUMP THERAPY FOR THE MANAGEMENT OF DIABETES

[1] Sainath N. Ingole, [2] Pogulwad Kalyani Kailas
[1] Assistant professor, 2 Student
[1] Shri Sambhaji College of Pharmacy, Khadkut

Abstract
The insulin pump, also known as continuous subcutaneous insulin, has developed in acceptance and sophistication as a flexible, near-physiologic programmable insulin delivery technology. The use of glucose sensor continuous monitoring offers unparalleled prediction and access to a patient's blood glucose levels. Actions are being taken. To combine the two technologies, moving from "sensordriven" and "sensor-augmented" pumps to autonomous, fully automated system for detecting and delivering objects. pumps that are implanted and an Additionally, early-phase "bionic pancreas" are actively being developed. "Pancreas replacement" is refined. It looks to be among the numerous options providing hope for those with diabetes. Endocrinologists and diabetic specialists will always have knowledge in this area, but it is advisable for primary care physicians to possess a functional understanding of insulin pumps and sensors. Insulin pump guarantee the best possible clinical treatment and patient decision-making.

Introduction
For countless individuals living with Type 1 diabetes mellitus (T1DM), a revolutionary treatment has brought newfound hope and freedom. Continuous subcutaneous insulin infusion, or insulin pump therapy, has transformed lives by providing a manageable and effective way to control this chronic condition. The groundbreaking Diabetes Control and Complication Trials in 1993 revealed that intensive insulin therapy, through multiple daily injections or pumps, could achieve near-normal blood sugar levels and delay complications. This breakthrough has empowered children, adolescents, and adults with T1DM to take charge of their health, enjoying greater flexibility and freedom. With insulin pumps, they can maintain tighter blood glucose control, reduce complication risks, and improve overall quality of life. Today, insulin pump therapy is globally recognized as a vital part of comprehensive diabetes care, opening doors to a brighter, healthier future where individuals with T1DM can thrive. [1] The insulin pump revolution has gained remarkable momentum worldwide. In just seven short years, the number of individuals embracing this lifechanging technology skyrocketed. In the US alone, the number of pump users surged from a modest 15,000 in 1993 to an astonishing 81,000 by the end of 2000. This explosive growth testifies to the transformative power of insulin pump therapy, empowering tens of thousands of people with diabetes to take control of their condition and live fuller lives. [2] For millions of people worldwide living with Type 1 diabetes, insulin pumps have become a lifeline, revolutionizing their daily lives.

In the US, a remarkable one-quarter of individuals with T1DM have taken control of their condition, embracing this groundbreaking technology. Imagine being able to manage your diabetes with greater ease, precision, and freedom – that's the reality for approximately 20-25% of Americans with T1DM.Beyond US borders, countries like Sweden and Germany are also witnessing a transformative shift. One in ten individuals with T1DM in these

nations are now empowered to live life on their own terms, thanks to insulin pumps. This technology has brought hope, confidence, and a renewed sense of possibility to those who need it most.[3] Years of rigorous research have shed light on the benefits of Continuous Subcutaneous Insulin Infusion (CSII) over Multiple Daily Injections (MDIs) for managing diabetes. Initially, some studies showed minimal differences in blood sugar control, measured by glycated hemoglobin (HbA1c) levels. However, a growing body of evidence now confirms that insulin pump therapy consistently outperforms conventional injections, leading to improved blood sugar management. Moreover, insulin pumps have been shown to significantly reduce or maintain hypoglycemic episodes, a major concern for diabetes patients. As the technology advances, patients increasingly prefer insulin pumps over traditional injections, embracing the enhanced control, flexibility, and peace of mind they provide. Today, the consensus is clear: insulin pump therapy offers a more effective, reliable, and patient-friendly approach to managing diabetes. [4-11] The insulin pump revolution has transformed the lives of countless individuals with diabetes. Breakthroughs in technology have given rise to sleek, intuitive, and life's changing devices. Patients who've made the switch to insulin pump therapy are thrilled with the freedom and confidence it brings.

1. No longer burdened by cumbersome equipment, they're embracing:
2. Discreet management, without unwanted attention
3. Simplified dosing, eliminating complex calculations
4. Improved blood sugar control, reducing worries
5. Fewer hypoglycemic episodes, bringing peace of mind
6. Enhanced overall well-being, empowering a fuller life

For those living with diabetes, insulin pumps have become a beacon of hope. They're reclaiming their lives, unfettered by the constraints of traditional management. The future of diabetes care has never looked brighter. [12,13] New research brings welcome news for individuals living with diabetes: Continuous Subcutaneous Insulin Infusion (CSII) has been proven to be a cost-effective solution, both now and in the future. Recent studies have conclusively shown that investing in insulin pump therapy yields significant financial benefits, reducing healthcare costs and improving overall well-being. By opting for CSII, individuals can alleviate the economic burden of diabetes complications, minimize hospitalizations and emergency visits, and lower medication expenses. This groundbreaking research reassures those considering insulin pump therapy that it's not only a life'schanging investment in their health but also a wise financial decision. [11,14,15] As insulin pumps continue to revolutionize diabetes management, a crucial debate unfolds. Experts question the accuracy of cost-effectiveness models, with Colquitt et al.'s systematic review revealing limitations in using HbA1c-based disease progression models to evaluate CSII's financial benefits over MDIs. Meanwhile, innovation charges forward, with top companies offering tailored insulin pumps. But with prices ranging from €3,195 to €3,834 ($4,790 to $5,749), individuals face tough questions: Are the benefits worth the cost? How can we ensure life-changing technology is accessible to all? As the diabetes landscape shifts, finding answers is vital for those counting on these advancements. Effective solutions demand careful consideration of both efficacy and affordability. [16 -18] For decades, insulin pumps have been a beacon of hope for individuals with diabetes, empowering them to take control of their condition with unparalleled ease and precision. Despite their profound impact, the remarkable story of insulin pump evolution remains untold - until now. This paper fills the gap, embarking on a fascinating journey through three decades of groundbreaking innovation. From modest origins to today's sleek, cutting-edge devices, we delve into the pioneering achievements, breakthroughs, and transformative features that have shaped insulin pump technology. By exploring the past, present, and future of these life-changing devices, we honor the resilience of those living with diabetes and illuminate the path to an even brighter tomorrow, where managing diabetes is easier, more effective, and more empowering than ever before. To uncover the story of insulin pumps, we embarked on a thorough literature review. We scoured top electronic databases - Cochrane Library, PubMed, Ovid, Embase, and more - using key terms like 'insulin

pumps', 'continuous subcutaneous insulin infusion', and 'insulin pump market'. We also explored economic outcomes, cost-effectiveness, and glycemic control. Every reference led us to more valuable insights. Our search didn't stop there.

Development of insulin pump

Now, let's journey through the remarkable history of insulin pump technology. In the 1960s, a pioneering spirit emerged in the US. Arnold Kadish, a visionary, designed the first closed-loop insulin pump - a groundbreaking device that continuously delivered insulin and monitored blood glucose levels. This innovative spark ignited a decades-long quest for perfection. From humble beginnings to today's sleek devices, insulin pumps have transformed lives. Join us as we explore the triumphs, breakthroughs, and future possibilities of this life-changing technology. [19,20] Meet the pioneering artificial pancreas, a life's-changing innovation born from necessity. This groundbreaking device combined a large pump with a cutting-edge autoanalyzer, tirelessly monitoring blood sugar levels. At its core, an intelligent on-off servo-mechanism sprang into action whenever blood sugar levels deviated from the norm, expertly adjusting insulin delivery to restore balance. Though its size was substantial, its impact was monumental, paving the way for future generations of insulin pumps and transforming the lives of countless individuals living with diabetes. [20,23] Despite its revolutionary potential, Kadish's artificial pancreas was relegated to the shadows due to its cumbersome design. Imagine carrying a device the size of an army backpack, constantly tethered to your body. The weight, bulk, and sheer impracticality made it nearly impossible for daily use, relegating this groundbreaking innovation to the realm of medical curiosity rather than lifechanging solution. Though its size was monumental, its impact was sadly muted, awaiting future innovators to refine and perfect the concept. [19,20] [fig 1] A new era dawned in 1974 with the arrival of the Bioslator, the world's first computer-controlled, closed-loop insulin pump. This pioneering device captured the attention of the medical community, offering fresh hope for individuals living with diabetes. The Bioslator's innovative technology automatically monitored and adjusted insulin levels, mimicking the body's natural rhythm. Its development marked a significant milestone, bridging the gap between science fiction and life-changing reality. With the Bioslator, the dream of seamless diabetes management began to take shape, paving the way for future breakthroughs. [24-26] [Fig 2] Imagine a device that thinks like your body's own pancreas. Meet the Bioslator, a revolutionary system designed to mimic nature's harmony. This groundbreaking technology consisted of five interconnected components:

1. A gentle pump that continuously drew and mixed blood, mimicking the body's natural flow.
2. A precise glucose analyze and monitor blood sugar levels.
3. A clever computer program that used complex algorithms to calculate the perfect dose of insulin or dextrose.
4. An intelligent infusion pump that delivered life-giving medication with precision.
5. A diligent plotter that recorded every minute-by-minute fluctuation in blood glucose levels



Fig. 1. The first insulin pump; kaddish's device [19]



Fig.2. Biostator [27]

Together, these components formed a symphony of innovation, working tirelessly to simulate the delicate balance of normal pancreatic function. The Bioslator was more than just a machine – it was a guardian of health, a promise of hope, and a testament to human ingenuity. [27] The Biostator's groundbreaking technology was hindered by its own bulk and complexity. Its intricate mechanics and cumbersome size made it unwieldy for everyday use, relegating this innovative device to the confines of short-term research studies. Despite its potential to revolutionize diabetes management, the Biostator's impracticality limited its impact, leaving those living with diabetes waiting for a more accessible solution. Its limitations served as a catalyst, driving researchers to pursue smaller, more agile designs that would seamlessly integrate into daily life. [20] The quest for effortless insulin delivery drove innovators to explore continuous intravenous insulin delivery systems. In 1974, Parisbased researcher Slama et al. made a groundbreaking breakthrough, demonstrating exceptional blood sugar control using an open-loop pump. Patients wore the pump in a shoulder bag, receiving insulin at a basal rate and a boosted dose during meals.

Although Slama's study showed promise, intravenous infusion risks – thrombosis, phlebitis, and infections – hindered widespread adoption. Undeterred , UK researchers introduced rigorous clinical testing in the late 1970s. Keen and Pickup from Guy's Hospital, London, pioneered the use of portable insulin pumps for Continuous Subcutaneous Insulin Infusion (CSII) in Type 1 diabetes patients. Their success was replicated by others, achieving precise glycemic control.

The Mill Hill Infuser, adapted from a hormone infusion pump for animals, emerged as a revolutionary device. This portable, battery-driven miniature syringe pump delivered insulin at dual rates – basal and prandial – with the press of a button. As pumps gained global acceptance, pharmaceutical companies invested heavily in development. The Auto syringe, nicknamed 'Big Blue Brick,' hit the market in 1978, selling 600 units monthly. The early 1980s witnessed the dawn of microprocessor-controlled insulin pumps, custom-designed by the Mill Hill and Guy's Hospital team. This innovation mentioned the beginning of a new era in diabetes management. These pioneers transformed lives, liberating individuals from the shackles of diabetes. Their perseverance paved the way for sleeker, smarter devices, empowering millions to live fuller lives. [19-36]. In 1983, the Nordisk Infuser was born, marking a milestone in insulin pump technology. This breakthrough sparked a wave of innovation, as leading medical and pharmaceutical companies rushed to introduce their own products. However, early commercial insulin pumps faced significant growing pains. These pioneering devices were cumbersome, weighing up to 400 grams and resembling house bricks. Frequent battery recharging, limited safety alarms, and

restricted control over insulin delivery made life challenging for users. Infusion sets featured metal needles, causing discomfort, and some pumps required a screwdriver for dosage adjustments – a frustrating hindrance. Despite these limitations, users persevered, driven by the promise of improved diabetes management. As technology advanced, pumps evolved, becoming smaller, smarter, and more userfriendly. The journey was far from perfect, but each setback sparked innovation, paving the way for today's sleek, life-changing devices. The Nordisk Infuser's legacy extends beyond its own success, inspiring a generation of innovators to create better, more empowering solutions for those living with diabetes. [19,29,36,37] The early days of insulin pumps were marred by frustrating setbacks and alarming complications. Users faced syringe and tubing blockages, and needles would dislodge unexpectedly, leaving them anxious and vulnerable. The consequences were dire: blood sugar levels skyrocketed, triggering hypoglycemic episodes and diabetic ketoacidosis. Infection at the injection site added another layer of risk, causing discomfort and fear.

Healthcare professionals and patients alike lost confidence in this fledgling technology. The promise of improved diabetes management seemed elusive, overshadowed by the reality of malfunctioning devices. Throughout the 1980s, insulin pumps struggled to gain traction. Users faced a daunting trade-off: the potential benefits of continuous insulin delivery versus the very real risks of complications. It was a precarious balance, one that left many questioning the reliability of these early devices. Despite these challenges, innovators persevered, driven by the conviction that better solutions were within reach. The lessons learned from these early struggles paved the way for the sophisticated, life-changing insulin pumps of today. [19, 20, 36, 37, 38]

The 1980s were a challenging time for insulin pumps. Patients hesitated to embrace these bulky, heavy devices, feeling tethered and restricted. Complications like pump malfunctions, insulin leaks, and tubing blockages further eroded confidence. As a result, early pumps were largely reserved for severe cases, often yielding disappointing results. But the 1990s marked a turning point. Innovators tackled technical issues head-on, crafting more reliable, user-friendly pumps. Safety features became standard: alarms sounded for infusion set occlusions, low batteries, and dwindling insulin reserves. A shift in mindset occurred, recognizing that limiting pump use to extreme cases hindered success. Clinicians and patients began exploring pumps as a viable option for broader diabetes management. Fast-forward to today: patients and clinicians enjoy a diverse range of devices. Sleek, pager-sized pumps boast enhanced safety measures and long-life batteries. Plastic catheter infusion sets reduce infection risks. Vibrant colors and crystal-clear screens make operation effortless. The transformation is remarkable. From cumbersome to compact, from frustrating to empowering. Insulin pumps have evolved, prioritizing user experience and well-being. Individuals with diabetes now have the tools to manage their condition with confidence, freedom, and hope. [20,39,40]

Today's insulin pumps empower patients to take control of their diabetes management. These intelligent devices allow users to program multiple basal rates throughout the day, mirroring the body's natural fluctuations in insulin needs. Modern pumps also calculate precise bolus doses based on carbohydrate intake and adjust for high blood glucose levels. Some "smart pumps" even estimate remaining active insulin from previous doses, automatically factoring in blood glucose, food intake, and other variables. For tailored treatment, advanced pumps offer flexible bolus options. The "square wave" mode delivers insulin over an extended period, while "dual wave" releases two boluses: one immediately and other hours later. This adapts to lifestyle needs, ensuring seamless management.

These intelligent pumps humanize diabetes management, acknowledging the complexities of daily life. By harmonizing technology with individual needs, patients regain confidence and freedom. [41-43] The astonishing 50% annual growth in the insulin pump market speaks volumes about the transformative impact of this technology. It's clear that these innovative devices are filling a deep-seated need, empowering individuals with diabetes to take charge of their lives. By providing precise insulin delivery, enhanced safety features, and unparalleled flexibility, insulin pumps have proven themselves as a game-changer. They're not just medical devices - they're lifelines, restoring freedom, confidence, and peace of mind to those who need it most. As this

technology continues to evolve, it's heartening to know that a brighter, more manageable future is within reach for countless individuals and families affected by diabetes. [2,19,36,39]

Current insulin Pump devices

Today, seven pioneering manufacturers are revolutionizing diabetes management worldwide. Medtronic Mini Med, a US-based leader, has transformed lives with its Paradigm pumps, holding an impressive 85% market share in the US. Roche's Disetronic dominates globally, outside the US, with a 15% share. The landscape has evolved since 2000, when Medtronic Mini Med and Disetronic were the dominant forces. Animas entered the scene in 2001, introducing its first-generation insulin pumps. Sooil and Nipro followed, crafting innovative devices for continuous subcutaneous insulin delivery – the Dana Diabecare Pumps and Amigo Pumps, respectively. A notable newcomer, Insulet, made waves with its groundbreaking OmniPod disposable insulin pumps, securing FDA approval in January 2005. This expanding market signals hope for millions living with diabetes, These seven manufacturers are driving progress, empowering individuals to manage their diabetes with confidence and dignity. Their contributions have reshaped the future of diabetes care, fostering a brighter tomorrow. [36,44] In the UK, a transformative landscape has emerged for diabetes management. Once, Roche's Disetronic Medical Systems was the sole provider.

The UK's National Health Service (NHS) has taken a significant step, publishing a comprehensive buyer's guide for insulin pumps. This valuable resource This expansion of options and resources embodies the NHS's commitment to enhancing lives. With increased accessibility and informed decision-making, individuals with diabetes can now navigate their journey with greater ease, empowerment, and hope. [45,46,47] In the UK, Starbridge System Ltd is pioneering a revolution in insulin delivery. Founded in 2002, this innovative company has developed the groundbreaking Starlet Pump. This wearable, patch-sized marvel uses laser-heated wax to precision-deliver insulin, providing 24/7 coverage.

Although still in development, this technology holds immense potential. Its impact could be lifechanging for millions. Currently, various insulin pumps are available, each with unique strengths:

1. Medtronic Paradigm pumps: integrated continuous glucose monitoring (though sensor-pump communication is limited)
2. Animas IR-2020: ideal for young children, with smallest basal increments (0.025 unit/h)
3. Sooil's Dana Diabecare IISG: the smallest and lightest pump on the market
4. Simplifies decision-making for patients and healthcare professionals
5. Ensures informed choices
6. Fosters confidence in diabetes management

Supports improved health outcomes Modern pumps often feature:

1. Built-in calculators for precise bolus estimation
2. Advanced safety measures: alarms, key lock functions
3. Enhanced user experience

As research advances, individuals with diabetes can expect more tailored, intuitive solutions. The future of diabetes management looks brighter than ever.

[Refer to Tables 1 and 2 for detailed specifications and pros/cons of latest insulin pumps.] [20,39,47,48,49]

Table 1. Features of the latest insulin pump on the market (18,56-63)

Company	Medtronic Minimed	Roche Disetronic Medical System	Animas (Johnson& Johnson)	Deltec (Smiths group)	Sooil	Nipro
Model	Paradigm 522/722 (REAL-Time System) 	Accu-Chek Spirit (3components) pump, metre, PDA 	IR-2020 	Cozmo1800 	Dana Diabecare IISG 	Amigo 
Dimension (mm)	522: 51·79·20 722: 51·79·20	80·56·20	80·46·24	51·77·18	45·75·19	55·83·24
Weight (g)	522:99Æ2 722:107Æ7	79Æ4(empty), 136Æ1(with battery, full cartridge, infusion set)	87.9	71.65	51	96.4
Reservoir size Screen size (sq mm)	176 or 300u 774	315u N.A	200u 992	300u 870	300u N.A	N.A N.A
Colours	Clear, smoke, blue, purple	Blue, with30 pump skins in colours and styles	Blue, silver, black, limelight, pink	Volcano black, pacific blue, tropical green	Black, white, pink, green, grey	6colours: yellow, white, pink, grey, blue, violet, dark blue
Basal Increment	0.05µ	0.1 µ from 0.1 to 25.0u/h	0.025µ	0.05µ	0.1 u/h and 0.01 u/h	0.05 u/h up to 30 u/h
Total Profile Interval Delivery	48/day 3 30 min Varies every 10 min	24/day 5 60 min Every 3 min	12/day 4 30min Every 3 min	48/day 4 30min Every 3 min	24/day 4 15min Every 4 min	48/day 4 N.A Every 3 to 15 min
Bolus Increment	0Æ1 visual, 0Æ5or 1Æ0 visual or audio,	0Æ1, 0Æ2, 0Æ5, 1Æ0	0Æ05 visual or audio, 0Æ1, 1Æ0, 5Æ0 audio	0Æ05, 0Æ1 visual, 0Æ05, 0Æ1, 0Æ5,	0Æ1–87 u	0Æ1to5Æ00 u

	remote extra			1Æ0 visual or audio		
Type	Standard, extended, or combination	Quick, scroll, extended, multiwave	Standard, extended, combination	Standard, extended, combination	Single step, extended, dual pattern	Normal, extended, layered
Calculator	Yes, using IOB correction factor, current glucose, and carb. input	On separate PDA	Yes, automatically calculates correction bolus based on personal settings by entering blood glucose reading	Yes, using IOB correction factor, current glucose, and carb. input	Yes, must enter factors each time	Yes, using IOB correction factor, current glucose, and carb. input
Battery type	AAA for pump A23 for remote	AA · 1 Alkaline or Rechargeable	AA lithium · 1	AAA · 1	3 Æ6 VDC · 1	CR2 battery
Battery life	3 weeks	4 weeks	6–8 weeks	3 weeks	8–12 weeks	4 weeks
Memory	4000 events, volatile (basal & history loss can occur): 24 boluses, 7day totals	Non-volatile: 90 days (4500 events); history recall of last 30 boluses, alerts, daily insulin totals, and temporary basal rate increases	Non-volatile: 600 bolus, 270 basals, 120 daily totals, 30 alarms, 60 primes	Non-volatile: 90 days (2000 events) of basals, carb boluses, correction boluses, alarms	Static memory stores last 100 boluses, last 100 daily totals, last 100 primes, last 100 alarms, carb amounts	90 days on screen and stores 1 year of history, even in the absence of a battery
Safety features	Key lock function	Key lock function	Alaram	Key lock function	Key lock function	Key lock function
Water poof	No; Splash resistant	Up to an hour	12 ft up to 24 h	Watertight	Watertight	1 m for 35 min
Warranty Price [Euros (Dollars)]	4 years €3518 ($5277)	4 years €3038 ($4558)	4 years €3326 ($4990)	4 years €3518 ($5277)	4 years NA	N.A €3553 ($5327)

Table 2. Comparison of the unique features and drawbacksof the latest insulin pumps. (20,39,47,48,49)

Pump model	Unique advantages	Potential drawbacks
Paradigm 522/722	Links with optional continuous glucose monitor Remote control bolus delivery included Separate bolus button Bolus calculator included Quickest/simplest bolus programming Cartridge/tubing connection adaptor is not required	Not watertight Volatile memory; can be lost Slowest bolus delivery Large minimum basal increment (0Æ05 u/h) No food database
Accu-Chek Spirit	Accepts rechargeable battery Choice of standard, advanced or custom selectable user menus Icon and menu-driven programming Reversible display screen with adjustable contrast Alarm can be set to audible beep with concurrent vibration	Basal rate below 0Æ1 u/h is not offered Must program 24 separate basal rates (1 for each hour) No bolus calculation on the pump itself No direct link with a blood glucose meter Cannot calculate exact insulin level; must be done manually Some functions require combination button presses and buttons rated are difficult to press
Animas IR-2020	Compact size with very bright, full colour screen Allows the smallest basal increment (0Æ025 u) Tracks residual bolus insulin Bolus calculator offered Separate bolus button on pump In-pump food database Button are large and easy to press Long battery life with lithium battery	Battery change requires re-priming No direct link with blood glucose meter No data averages or statistics are generated Can not recall blood glucose or carbo hydrates history Insulin on-board is not subtracted uniformly Bolus delivery may be too rapid for some Some display text is small
Cozmo 1800	Integrated Freestyle meter transmits blood glucose directly into pump Tracks residual bolus insulin Many reminders: missed bolus, daily correction bolus total, detailed history in pump Bolus calculator included Wide bolus volume range (0Æ05–75 u) Separate bolus button Provides recommendations to prevent/treat hypoglycaemia Customizable food list/meal maker program	Low screen contrast; difficult to see without backlight Slightly thicker design than other pumps Advanced features can be complex to program Button are relatively difficult to press
Dana Diabecare IISG	Smallest and lightest pump in the market Temporary basal for up to 12 h Has energy saving sleep mode Default boluses for breakfast, lunch and dinner	None documented

Amigo	Temporary basal mode	Reminders just say 'reminder' without giving an indication
OmniPod	Bolus estimator Very discrete size Large screen with full-sentence text Can be worn without tubing Watertight Freestyle meter is build on handled programmer Auto-dose capability Preset meal and default bolus PIN# programming and access to functions including daily maximums and mode settings Has food database	No food database Must use handled programmer to do any programming Cannot do programming or editing while bolus is delivering Has only one cannula type; may not work for all body types Pod stops working after 72 h No vibrate option on pod or handled programmer No data down load option

Insulin Pump Design [50]

Breaking Down Barriers: Affordable Insulin Pumps for All Imagine living with diabetes without the financial burden of expensive insulin pumps. Our innovative design makes that possible. We've created an open-source, low-cost insulin pump, shattering the barriers of affordability. Commercial pumps can cost upwards of $6,500, but our device can be produced for just $89.85. But that's not all. Our design can seamlessly integrate with mobile devices via Bluetooth or wired connections, leveraging phone security and processing power. Our mission is clear: make insulin pumps accessible to everyone, regardless of financial means. With this breakthrough design, we're one step closer to a world where diabetes management is within reach for all. Join the movement toward affordable healthcare. Together, let's revolutionize diabetes care. Assembling Your Insulin Pump: A Simple Guide

Step 1: Plunger Sub-Assembly (Fig no 3)

1. Insert square M4 nuts into the plunger's slot, center, and ends.
2. Screw the threaded shaft through the nuts.
3. Add lubricant for smooth movement.
4. Wind back the plunger to prepare for case assembly.

Fig. 3. Build instructions for Plunger Sub-assembly.

Step 2: Pump Assembly

Follow these easy steps (see Fig. 4):

1. Insert plunger/motor sub-assembly into case channel.

2. Align 'wings' with slots.
3. Place motor body in its slot.
4. Ensure gearbox fits inside housing.
5. Add PCB, battery holder, and insulin cartridge.
6. A standard Mini Med180U Reservoir
7. Final assemblies of the device are shown



Fig. 4. Build instructions for Ultra-low-cost insulin pump.

Your device is now assembled (see Fig. 5).



(a) (b)

Fig. 5. Internal components fitted into case (a) and final design with closed case and commercial insulin cartridge and infusion set fitted (b).

Insulin Pump Therapy for Type 2 Diabetes

Insulin pump therapy was first designed for individuals living with type 1 diabetes, but its benefits now extend to those with type 2 diabetes who rely on insulin. This life-changing technology can bring newfound freedom and control to anyone requiring insulin therapy, regardless of their diabetes type. [51,52] In Insulin Pump Therapy for Type 2 Diabetes For individuals living with sub optimally controlled type 2 diabetes, insulin pump therapy has

shown remarkable promise. Studies reveal that switching from multiple oral medications or manual insulin injections (MDI) to insulin pumps can:

1. Lower A1C levels by 1% or more
2. Reduce total daily insulin needs
3. Minimize hypoglycemia risk
4. Boost treatment satisfaction

Remarkably, these benefits are achievable with simple insulin dosing regimens, requiring only one or two basal rates. This simplicity dispels the notion that individuals with type 2 diabetes need complex pump features, typically reserved for type 1 diabetes management. This groundbreaking research has significant implications:

1. Simplified insulin pump therapy can overcome barriers to access for type 2 diabetes patients
2. Reduced educational requirements and lower costs make insulin pumps more accessible
3. Empowering individuals with type 2 diabetes to take control of their health, with fewer complications and improved well-being

A new era in type 2 diabetes management has begun, offering hope and renewed possibility for those seeking effective, user-friendly solutions." [53-58] A development in type 2 diabetes management has arrived. Simplified insulin pump technology, specifically designed for individuals with type 2 diabetes, offers a game-changing solution. These innovative, disposable patch pumps are small, discreet, and effortless to use. With a simple button press, the infusion cannula auto-inserts, and the pump delivers pre-programmed basal insulin doses. Bolus dosing is equally straightforward, with pre-set increments of 2 units per button press.

The V-Go, currently the only commercially available option in the US, comes in three models: V-Go 20, 30, or 40. These numbers indicate the fixed basal insulin amount delivered over 24 hours. For example, the V-Go 20 delivers 20 units of insulin at a rate of 0.83 units per hour. Additionally, the V-Go features a mealtime bolus button, allowing up to 36 units of insulin delivery per day in 2-unit increments. Clinical trials have yielded impressive results: improved glycemic control, high patient satisfaction, reduced barriers to insulin pump treatment, and cost savings compared to traditional MDI therapy. These simplified patch pumps empower individuals with type 2 diabetes to manage their condition with confidence and ease, streamlining insulin therapy into daily life. [59-62]

Meta-Analysis

In a groundbreaking meta-analysis, 52 rigorous studies encompassing 1,547 individuals with type 1 diabetes unveil the transformative benefits of Continuous Subcutaneous Insulin Infusion (CSII) therapy. This pioneering treatment approach has been shown to profoundly enhance glycemic control, slashing blood glucose levels by a remarkable 17.31 mg/dl and reducing insulin requirements. The analysis reveals that both pediatric and adult patients exhibit substantial improvements in their overall diabetes management, with CSII therapy lasting at least one year yielding the most dramatic and lasting benefits. Notably, the studies demonstrate that CSII therapy has a profound impact on glycemic control, resulting in significantly lower glycohemoglobin levels. This reduction in glycohemoglobin levels translates to a decreased risk of diabetes-related complications, such as heart disease, kidney damage, and vision impairment. Furthermore**,** the analysis highlights the versatility of CSII therapy, with benefits observed in patients across various age groups, from young children to adults. While some studies note weight gain as a potential side effect, others report decreased weight, underscoring the complexity of this treatment and the need for personalized care. However, the overwhelming evidence suggests that CSII therapy offers a significant advantage over traditional insulin therapy, providing individuals with type 1 diabetes a more effective and manageable treatment option. This comprehensive analysis has profound implications for the management of type 1 diabetes, paving the way for improved health outcomes, enhanced quality of life, and renewed hope for individuals living with this chronic condition. By harnessing the power of CSII therapy, healthcare providers can empower patients to take control of their diabetes, mitigate the risk of complications, and live fuller, healthier lives.[63]

Conventional Insulin Pump Therapy

Insulin pumps are revolutionary, compact devices that continuously deliver rapid-acting insulin to individuals with diabetes, providing unparalleled control over blood glucose management. These innovative devices utilize a tiny catheter inserted beneath the skin, secured with adhesive, and connected to the pump via flexible tubing or advanced wireless technology. Insulin pumps harness the power of rapid-acting insulin formulations, precisely delivering insulin in two primary modes:

1. Continuous Basal Infusion: A steady, adjustable flow of insulin throughout the day and night, mirroring the body's natural insulin production.
2. Discrete Bolus Doses: Personalized insulin doses for meals, snacks, or corrections, calculated based on blood glucose levels, insulin on board, and carbohydrate intake.

Basal insulin delivery is tailored to individual needs, influenced by various factors such as:

1. Physiology
2. Developmental life stage (puberty, growth)
3. Activity level
4. Time of day
5. Sleep schedule

Temporary basal features enable swift adjustments during periods of changed insulin requirements, such as acute illness or physical activity. Advanced bolus calculators provide personalized dose recommendations, ensuring optimal glycemic control.

Insulin pumps boast impressive features

1. Precise dosing increments (0.025 units)
2. Extended bolus options for high-fat meals or gastroparesis
3. Multiple basal rates for dynamic insulin adjustment
4. Temporary basal adjustments for changing needs
5. Wireless technology for seamless connectivity

With an array of insulin pump options available and groundbreaking technologies emerging annually, individuals with type 1 or 2 diabetes can confidently manage their condition, achieving improved glycemic control, enhanced flexibility, and an elevated quality of life. [64]

Effect on Quality of life

Diabetes: A Growing Global Health Concern

Diabetes is a devastating disease affecting millions worldwide, regardless of geographic or economic boundaries. In the North American and Caribbean region, a staggering 9.6% of the population lives with diabetes. Globally, 347 million people were diagnosed with diabetes as of 2013, and this number continues to rise. The Consequences of Uncontrolled Diabetes If left unchecked, diabetes can lead to severe complications, including heart disease, kidney damage, blindness, and even death. In fact, diabetes is projected to become the 7th leading cause of death by 2030.

The Importance of Glycemic Control

Effective diabetes management relies on achieving good glycemic control. This reduces the risk of serious long-term complications and improves overall health outcomes. Research shows that:

1. A 1% reduction in hemoglobin A1c (HbA1c) decreases diabetes-related deaths by 21%
2. Microvascular complications decrease by 37%
3. Myocardial infarction risk decreases by 14%

The Challenge of Hypoglycemia

However, hypoglycemia (low blood sugar) remains a significant obstacle to achieving good glycemic control. Its prevalence has increased with the growing use of insulin therapy in type 2 diabetes (T2D) management. Hypoglycemia can have dire consequences, including:

1. Stroke
2. Acute cardiac failure
3. Myocardial infarction

Prioritizing Quality of Life

Managing diabetes is not just about controlling blood sugar levels; it's also about maintaining a good quality of life. This includes considering the emotional, social, and physical impacts of the disease on individuals.[65]

Psychosocial factors and the insulin pump

Positive Psychosocial Factors:

1. Improved self-esteem and confidence
2. Enhanced sense of control over diabetes management
3. Reduced anxiety and stress related to blood glucose fluctuations
4. Increased flexibility and freedom in daily life
5. Better sleep quality due to improved glycemic control
6. Improved relationships with family and friends
7. Increased motivation to manage diabetes effectively

Negative Psychosocial Factors:

1. Initial anxiety or intimidation by the device
2. Fear of pump malfunction or infusion site issues
3. Body image concerns related to wearing the pump
4. Social stigma or self-consciousness about using an insulin pump
5. Financial stress due to pump and supply costs
6. Emotional burden of continuous glucose monitoring
7. Potential for pump-related stress or burnout

Psychosocial Benefits for Specific Populations:

1. Children and adolescents: improved independence and self-management skills
2. Adults: increased flexibility and convenience in busy lives
3. Older adults: simplified medication management and reduced cognitive load

Addressing Psychosocial Concerns:

1. Comprehensive education and training on insulin pump use
2. Ongoing support from healthcare providers and peers
3. Counseling or therapy to address emotional concerns
4. Online resources and communities for connection and sharing experiences
5. Continuous glucose monitoring and data analysis to optimize pump settings

Future Research Directions:

1. Investigating long-term psychosocial outcomes of insulin pump use
2. Developing personalized interventions to address psychosocial concerns
3. Exploring the impact of insulin pumps on mental health and well-being
4. Examining the role of social support in insulin pump adherence and success

Conclusion

Taking charge of your diabetes management, having realistic expectations about insulin pump use, and reflecting on your diagnosis experience can significantly improve your blood sugar control. Research has shown that individuals who actively participate in their self-care, understand the benefits and limitations of insulin pumps, and acknowledge the emotional impact of their diagnosis achieve better glycemic control. To optimize diabetes management, healthcare providers should consider interventions that address these critical factors. This includes evaluating and discussing self-care approaches, exploring the emotional recall of diagnosis, setting realistic expectations, and addressing pump-related self-consciousness and body image concerns. By understanding the complex interplay between emotional, psychological, and practical aspects of diabetes management, healthcare providers can empower individuals to take control of their condition. Further research is needed to explore the roles of these factors in optimal diabetes management, ultimately leading to better health outcomes and improved quality of life for individuals living with diabetes. Effective diabetes management requires a holistic approach, considering the physical, emotional, and psychological aspects of living with the condition. By acknowledging the importance of active self-care, emotional recall, and realistic expectations, individuals can unlock better glycemic control and a healthier, more balanced life.

Reference

1. Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine, 329, 977–986.
2. Bode BW, Sabbah HT, Gross TM, Fredrickson LP, Davidson BC (2002) Diabetes management in the new millennium using insulin pump therapy. Diabetes/Metabolism Research and Reviews, 18(Suppl. 1), S14–S20.
3. Selam JL (2006) CSII in Europe: where are we, where are we going? An analysis of articles published in Infu systems International. Diabetes Research and Clinical Practice, 74(Suppl. 2), S23–126.
4. Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N (2004) Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technology Assessment, 8.
5. Bode BW, Steed RD, Davidson PC (1996) Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care, 19, 324–327.
6. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV (1999) Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care, 22, 1779–1784.
7. Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP (2001) Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics, 107, 351–356.
8. Pickup J, Mattock M, Kerry S (2002) Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomized controlled trials. British Medical Journal, 324, 705.
9. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M (2002) Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. Journal of Pediatrics, 141, 490–495.
10. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV (2004) A randomized, prospective trial comparing the efficacy of continue subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care, 27, 1554–1558.
11. Ulahannan T, Myint N, Lonnen K (2007) Making the case for insulin pump therapy. Practical Diabetes International, 24, 252–256.
12. Low KG, Massa L, Lehman D, Olshan J S (2005) Insulin pumpusein young adolescents with type 1 diabetes: a descriptive study. Pediatric Diabetes, 6, 22–31.

13. Olinder AL, Kernell A (2007) Continuous subcutaneous insulin infusion in young girls: a two-year follow-up study. European Diabetes Nursing, 4, 34–39.
14. Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ (2005) Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabetic Medicine, 22, 1239–1245.
15. Scuffham P, Carr L (2003) The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabetic Medicine, 20, 586–593.
16. Kanakis SJ, Watts C, Leichter SB (2002) The business of insulin pumps in diabetes care: clinical and eco nomic considerations. Clinical Diabetes, 20, 214–216.
17. Scheiner G (2006) Go ahead, pick your pump. Which pump is right for you? Diabetes SelfManagement, 23, 12, 14–16, 19–20.
18. Eugster EA, Francis G (2006) Position statement: continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics, 118, e1244–e1249.
19. Lee S (2003) Continuous Subcutaneous Insulin Infusion: Intensive Treatment, Flexible Lifestyle.
Available at: http://cme.medscape.com/viewarticle/ 460365_print (accessed 11-1-2008). [Electronic Citation]
20. Input Newsletter. (2006) History of pumping, 4(6). United Kingdom: INPUT. [Report]
21. Kadish AH (1963a) A servomechanism for blood sugar control. Biomedical Sciences Instrumentation, 1, 171–176.
22. Kadish AH (1963b) Automation control of blood sugar a servomechanism for glucose monitoring and control. Transactions-American Society for Artificial Internal Organs, 9, 363–367.
23. Kadish AH (1964) Automation control of blood sugar. I. A servomechanism for glucose monitoring and control. American Journal of Medical Electronics, 3, 82–86.
24. Pfeiffer E, Thum C, Clemens A (1974) The artificial beta cell–a continuous control of blood sugar by external regulation of insulin infusion (glucose-controlled insulin infusion system). Hormone and Metabolic Research, 6, 339–342.
25. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W (1974a) An artificial endocrine pancreas. Diabetes, 23, 389–396.
26. Albisser AM, Leibel BS, Ewart TG et al. (1974b) Clinical control of diabetes by the artificial pancreas. Diabetes, 23, 397–404.
27. Fogt EJ, Dodd LM, Jenning EM, Clemens AH (1978) Development and evaluation of a glucose analyzer for a glucose-controlled insulin infusion system (Biostator). Clinical Chemistry, 24, 1366–1372.
28. Slama G, Hau couverture M, Assan R, Tchobroutsky G (1974) One to five days of continuous intravenous insulin infusion on seven diabetic patients. Diabetes, 23, 732–738.
29. Torrance T, Franklin V, Greene S (2003) Insulin pumps. Archives of Disease in Childhood, 88, 949–953.
30. Pickup JC, Keen H, Parsons JA, Alberti KG (1978a) Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. British Medical Journal, 1, 204–207.
31. Pickup J C, KeenH, Stevenson RW Parsons J A, Alberti KG, White M, Kohner EM (1978b) Insulin via continuous subcutaneous infusion. Lancet, 2, 988–989.
32. Tamborlane WV (1979) Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump. The New England Journal of Medicine, 300, 573–578.
33. Felig P, Tamborlane W, Sherwin RS, Genel M (1979a) Infusion-pump treatment of diabetes mellitus. The New England Journal of Medicine, 301, 268–269.
34. Felig P, Tamborlane W, Sherwin RS, Genel M (1979b) Insulin-infusion pump for diabetes. The New England Journal of Medicine, 301, 1004–1005.
35. Parsons JA, Rothwell D, Sharpe JE (1977) A miniature syringe pump for continuous administration of drugs and hormones: The Mill Hill infuser. Lancet, 1, 77–78.

36. Hauge C (2003) Insulin Pumps: Evolution of an Indus try. Medtronic Mini Med Europe. Switzerland: Business Briefing: European Pharmacology, 1–3. [Report]
37. Anonymous (2005a) Insulin Pump Therapy. Available at: http://www.medtronic-diabetes.com.au/ medical_prof-ptherapy.html (accessed 14-1-2008). [Electronic Citation]
38. Guilhem I, Leguerrier AM, Lecordier F, Poirier JY, Maugendre D (2006) Technical risks with subcutaneous insulin infusion. Diabetes and Metabolism, 32, 279–284.
39. Weintrob N, Shalitin S, Phillip M (2004) Why pumps? Continuous subcutaneous insulin infusion for children and adolescents with type 1 diabetes. The Israel Medical Association Journal, 6, 271– 275.
40. Reynold L (2000) Reemergence of insulin pump therapy in the 1990s. Southern Medical Journal, 93, 1157–1161.
41. Prasek M, Bozek T, Metelko Z (2003) Continuous subcutaneous insulin infusion (CSII).
Diabetologia Croatica, 32, 111–124.
42. CIGNA healthcare coverage position (2004) External insulin pump. Coverage position number: 0087, 1-15. [Report]
43. Skyler JS, Ponder S, Kruger DF, Matheson D, Parkin CG (2007) Is there a place for insulin pump therapy in your practice? Clinical Diabetes, 25, 50–56.
44. PhamM.Diabetes (2005) Proprietary Survey on Insulin Pumps and Continuous Blood Glucose Monitoring. US: HSBC Global Research, 1–27. [Report]
45. Harrison M (2004) Update on insulin pump therapy in theUK.Society for Endocrinology Annua lMeeting. London: UK, Endocrine Abstract 8 DS4, 1. [Report]
46. National Institute for Clinical Excellence (2007) Continuous Subcutaneous Insulin Infusion for the Treatment of Diabetes (review). UK: Health Technology Appraisal (Final scope), 1–5. [Report]
47. Skryabina E, Davey C, Wilson S, Chan J (2008) Buyers' Guide: Insulin Pumps. London: NHS Purchasing and Supply Agency: Centre for Evidence-based Purchasing, CEP 08004, 1–28.
[Report]
48. Anonymous (2005b) New generation of insulin pump: Star bridge global diabetes contract, 1-2.
Available at: http://www.medicalnewstoday.com/ printerfriendlynews.php?newsid=33847 (accessed 29-1-2008b). [Electronic Citation] 49. Mudaliar S (2007) New frontiers in the management of type 2 diabetes. Indian Journal of Medical Research, 125, 275–296.
49. Design of an open source ultralow cost insulin pump Matthew Payne⇑, Francis Pooke, Harrison Fulton, Hamish Shaw, Tom Coulson, Dr Jennifer Knopp, Lui Holder-Pearson, Jake Campbell, J.
Geoffrey Chase Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand
50. Reznik Y, Cohen O. Insulin pump for type 2 diabetes: use and misuse of continuous subcutaneous insulin infusion in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S219–S225
51. Bode BW. Insulin pump use in type 2 diabetes. Diabetes Technol Ther 2010;12(Suppl. 1):S17–S21
9. Alsaleh FM, Smith FJ, Taylor KM.
52. Edelman SV, Bode BW, Bailey TS, et al. Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. Diabetes Technol Ther 2010; 12:627–633
53. Vigersky RA, Huang S, Cordero TL, et al.; OpT2mise Study Group. Improved HbA1c, total daily insulin dose, and treatment satisfaction with insulin pump therapy compares to multiple daily injections in patients with type 2 diabetes irrespective of baseline C-peptide levels. Endocr Pract 2018;24: 446–452
54. Aronson R, Reznik Y, Conget I, et al.; OpT2mise Study Group. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial. Diabetes Obes Metab 2016; 18:500–507

55. Reznik Y, Cohen O, Aronson R, et al.; OpT2mise Study Group. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised openlabel controlled trial. Lancet 2014; 384:1265–1272

56. King AB, Clark D, Wolfe GS. The number of basal rates required to achieve near-normal basal glucose control in pump treated type 2 diabetes. Diabetes Technol Ther 2012;14 :900–903

57. Skyler JS, Ponder S, Kruger DM, Matheson D, Parkin CG. Is there a place for insulin pump therapy in your practice? Clin Diabetes 2007; 25:50–56

58. Knutsen PG, Voelker CQ, Nikkel CC. Clinical insights into a new, disposable insulin delivery device. Diabetes Spectr 2015; 28:209–213

59. Lilly LC, Mader JK, Warner J. Developing a simple 3-day insulin delivery device to meet the needs of people with type 2 diabetes. J Diabetes Sci Technol 2019:13: 11–19

60. Hermanns N, Lilly LC, Mader JK, et al. Novel simple insulin delivery device reduces barriers to insulin therapy in type 2 diabetes: results from a pilot study. J Diabetes Sci Technol 2015; 9:581– 587

61. Mader JK, Lilly LC, Aberer F, et al. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with type 2 diabetes. Diabetes Med 2018;35: 1448–1456

62. Insulin Pump Therapy A meta-analysis JILL WEISSBERG-BENCHELL, PHD, CDE1 JEANNE ANTISDEL-LOMAGLIO, PHD2 ROOPA SESHADRI, PHD Epidemiology/Health Services/Psychosocial Research.

63. Ly TT, Layne JE, Huyett LM, Nazzaro D, O'Connor JB. Novel Bluetooth-enabled tubeless insulin pump: innovating pump therapy for patients in the digital age. J Diabetes Sci Technol 2019;13: 20– 26

64. Impact of insulin pump on quality of life of diabetic patients Haider Ghazanfar, Syed Wajih Rizvi1, Aliya Khurram, Fizza Orooj, Iman Qaiser R Endocrinology Clinic, New Jersey, 1R Endocrinology Clinic and Endocrine Department of Robert Wood Johnson Hospital, New Jersey,
United States of America